Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial  by Wang, Jin-Xiang et al.
International Journal of Infectious Diseases 48 (2016) 40–45Perspective
Acute exacerbations of chronic obstructive pulmonary disease with
low serum procalcitonin values do not beneﬁt from antibiotic
treatment: a prospective randomized controlled trial
Jin-Xiang Wang a, Shu-Ming Zhang a, Xiao-Hui Li a, Yao Zhang b, Zhen-Yang Xu a,
Bin Cao c,d,e,*
aDepartment of Respiratory and Critical Care Medicine, Beijing Luhe Hospital, Capital Medical University, Beijing, China
bGlobal Health, Population and Nutrition, Global Research and Services, Family Health International 360, Durham, North Carolina, USA
cDepartment of Respiratory and Critical Care Medicine, China–Japan Friendship Hospital, Beijing, China
dDepartment of Respiratory Medicine, Capital Medical University, Beijing, China
eNational Clinical Research Centre for Respiratory Disease, Beijing, China
A R T I C L E I N F O
Article history:
Received 14 March 2016
Received in revised form 26 April 2016
Accepted 28 April 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark.
Keywords:
Procalcitonin
Chronic obstructive pulmonary disease
Antibiotics
Acute exacerbation
S U M M A R Y
Objective: The majority of patients with acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) have low serum procalcitonin (PCT) values. The aim of this study was to determine whether
these patients may beneﬁt from antibiotic treatment.
Methods: A total of 457 patients with AECOPD were screened; 194 patients with AECOPD and PCT <0.1
ng/ml were assigned randomly to an antibiotic group or a control group. In the per-protocol (PP)
population, the antibiotic group subjects were required to have used antibiotics for at least 3 days, and
the control group subjects were required not to have used antibiotics within the 10 days after admission.
The intention-to-treat (ITT) population was deﬁned as the patients who were randomized. The primary
outcome was the treatment success rate on day 10 after admission. Secondary outcomes were symptoms
assessed on a visual analog scale (VAS), length of hospitalization, mortality, exacerbation rate, and re-
hospitalization within 30 days of follow-up (study registered at chictr.org.cn: ChiCTR-TRC-14004726).
Results: 95 patients in the antibiotic group and 96 patients in the control group completed the study. In
the ITT population, the overall treatment success rate in the control group (95.8%) was similar to that in
the antibiotic group (93.7%), with no signiﬁcant difference (p = 0.732). Five patients in the antibiotic
group died, either in hospital or within 30 days of discharge. In the control group, two died within
30 days of discharge. Antibiotic use in the control group was 17.7% (17/96), and age 75 years was a
predictive risk factor for requiring antibiotic therapy in the control group (odds ratio 4.055, 95%
conﬁdence interval 1.297–12.678; p = 0.012). According to the PP analysis, the treatment success rate on
day 10 after admission was 98.7% (78/79) in the control group and 93.7% (89/95) in the antibiotic group,
also with no signiﬁcant difference (p = 0.193). No secondary outcome was signiﬁcantly different
between the two groups.
Conclusion: Antibiotic treatment is no better than placebo in AECOPD with a PCT level <0.1 ng/ml.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The prevalence of chronic obstructive pulmonary disease
(COPD) in China is 8.2% in adults over the age of 40 years.1 COPD
has become an important economic burden for both urban and* Corresponding author. Tel.: +860-10-84206264; fax: +860-10-84206264.
E-mail address: caobin_ben@163.com (B. Cao).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rural residents all over the world, and the management of acute
exacerbations of COPD (AECOPD) increases healthcare costs
signiﬁcantly.2–4 For patients with AECOPD in the USA and Europe,
antibiotic prescription rates of 85%5 and 86%,6 respectively,
have been reported. Moreover, two retrospective analyses
showed that antibiotic treatment beneﬁted patients with
AECOPD.7,8 However, not all patients with AECOPD will beneﬁt
from antibiotic therapy,9,10 and the overuse of antibiotics may
increase the risk of microbial resistance.ociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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studies have focused on identifying clinical characteristics and
inﬂammatory biomarkers to guide antibiotic treatment in these
patients. Studies have shown that patients with type I Anthonisen
exacerbation,9 purulent sputum,11,12 and those with very severe
lung function impairment requiring invasive or non-invasive
mechanical ventilation, are likely to beneﬁt from antibiotic
treatment.13 Procalcitonin (PCT) is a speciﬁc biomarker of bacterial
infection. It has been studied prospectively as a biomarker to guide
antibiotic treatment in patients with AECOPD and lower respira-
tory tract infections.14–16 Studies have shown that PCT-guided
therapy leads to a reduction in antibiotic use in patients with
AECOPD and lower respiratory tract infections.14–16
The aim of previous studies on PCT-guided antibiotic therapy in
patients with AECOPD and lower respiratory tract infections has
been to reduce antibiotic prescription. In these studies, patients with
a PCT level of >0.25 ng/ml were considered to have bacterial
infections, and antibiotic treatment was encouraged. A level of 0.1 to
0.25 ng/ml was considered to indicate a possible bacterial infection,
and antibiotics were discouraged or encouraged according to the
stability of the patient’s clinical condition. A PCT level of 0.1 ng/ml or
less was considered to indicate the absence of bacterial infection,
and the use of antibiotics was discouraged.14–16 However, a
subgroup analysis showed that patients with AECOPD and a PCT
level of <0.1 ng/ml beneﬁted from treatment with doxycycline.17
Therefore, the value of antibiotic treatment for hospitalized AECOPD
patients with low serum PCT values is controversial.
It was hypothesized that antibiotic treatment would beneﬁt
AECOPD patients with a PCT level of <0.1 ng/ml. In order to conﬁrm
this hypothesis, a single-center, prospective randomized con-
trolled trial was conducted. The study was registered at
chictr.org.cn (ChiCTR-TRC-14004726).
2. Materials and methods
2.1. Study design and objectives
From June 10, 2014 to September 5, 2015, all patients with
AECOPD admitted to the Department of Respiratory and Critical Care
Medicine of Beijing Luhe Hospital were screened. A diagnosis of
COPD according to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2014 criteria was required. AECOPD was deﬁned as
an acute change in symptoms that were beyond normal day-to-day
variation and that required a change in daily therapeutic drug
regimen.2 All patients included in this study were classiﬁed into
Anthonisen type I to type III.9 Patients with AECOPD who were 40
years of age, had sound understanding and language abilities, and
who had a PCT level <0.1 ng/ml were included. Exclusion criteria
were fever (38.0 8C), tracheal intubation within 24 h after hospital
admission, a PCT level of 0.1 ng/ml on admission, pneumonia,
chronic renal failure, history of malignant disease, immunosuppres-
sive therapy, and refusal to participate. The study protocol was
approved by the Ethics Committee of Luhe Hospital (Institutional
Review Board approval number 2014-01), and all patients provided
written informed consent.
A computer digital table method was used to generate
randomization numbers. Researchers in this study had 24-h access
to randomization numbers, allowing immediate and concealed
allocation to the trial. Each patient was allocated a unique trial
number. Persons responsible for allocation concealment were not
allowed to be involved in the measurement of results. Eligible
patients were assigned randomly to either the control group or the
antibiotic group.
Antibiotics were withheld from patients in the control group.
However, antibiotics could be administered later for patients
whose clinical condition was unstable16 or who had a worsening ofsymptoms and signs, and for those with positive evidence of
bacteria as assessed by the attending physicians. In the antibiotic
group, antibiotics were administered routinely. In order to cover
the most common pathogenic bacteria, piperacillin–sulbactam (CR
Double-Crane Pharmaceuticals Co., Ltd) was selected as the ﬁrst
choice of antibiotic; ceftazidime (Hainan Haiyao Pharmaceuticals
Co., Ltd) or levoﬂoxacin (CR Double-Crane Pharmaceuticals Co.,
Ltd) was substituted in the case of a penicillin allergy. Antibiotic
agents could be adjusted according to microbial culture results and
depending on the recommendations of the attending physicians.
The duration of antibiotic treatment was also determined by the
attending physicians. Other treatment methods in the two groups
were instituted by the attending physicians in accordance with the
GOLD guidelines.
2.2. Measurement
The baseline characteristics of the patients with AECOPD were
collected on the day of hospital admission. PCT was measured
using an immunoluminescence assay (VIDAS BRAHMS PCT) within
2 h after hospitalization. C-reactive protein (CRP) was measured by
the immune turbidity method. Blood was collected for routine
laboratory examinations, and chest computed tomography (CT)
was performed within 48 h of hospitalization. Lung function tests
were performed by trained technicians upon hospital admission
and on the day of hospital discharge according to the guidelines of
the American Thoracic Society.18
Symptoms were assessed by the patients themselves on a visual
analog scale (VAS); the symptoms assessed included dyspnea,
cough, fatigue, and sputum purulence.19 The symptom VAS score
was obtained upon hospital admission, at 3 days after hospitaliza-
tion, and on the day of discharge. The assessment scale ranged
from 0 (feeling completely healthy) to 10 (feeling extremely sick).
Treatment efﬁcacy was evaluated by per-protocol (PP) and
intention-to-treat (ITT) analysis on day 10 after hospitalization. In
the PP population, the antibiotic group subjects were required to
have used antibiotics for at least 3 days, and the control group
subjects were required not to have used antibiotics within the
10 days after admission. The ITT population was deﬁned as all
patients who were randomized.
Treatment success was deﬁned as cure (a complete resolution
of signs and symptoms associated with the exacerbation) or
improvement (a resolution or reduction of the symptoms and signs
associated with the exacerbation, without new symptoms or
signs). Treatment failure was deﬁned as a worsening of symptoms
and signs or death.20 Telephone follow-up was performed on day
30 after hospital discharge. Follow-up assessments included
exacerbations, re-admission, antibiotic use, and death.
The primary outcome was the treatment success rate on day
10 after admission. The secondary outcomes included symptoms
assessed by VAS (at hospital admission, 3 days after hospitaliza-
tion, and on the day of hospital discharge), the length of hospital
stay, intubation rate, mortality during hospitalization and in the
30-day follow-up period, the rate of antibiotic use, and re-
admission due to AECOPD within the 30-day follow-up period.
2.3. Statistical analysis
SPSS version 17.0 for Windows software (SPSS Inc., Chicago, IL,
USA) was used for data management and the statistical analysis.
Measurement data were expressed as the mean  standard
deviation, while categorical data were presented as a number or
percentage. An independent samples t-test was applied to compare
the difference in measurement data between groups; for comparisons
of enumeration data, the Pearson Chi-square test or continuous
correction Chi-square test was used. Binary logistic regression
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the control group who needed antibiotic therapy: sex, smoking status,
frequent hospitalization in the previous year (2 times), age 75
years, bronchiectasis, coronary heart disease, hypertension, diabetes,
chronic congestive heart failure, history of cerebral infarction, oxygen
therapy, home non-invasive mechanical ventilation treatment,
antibiotic use within 3 months prior to hospitalization, sputum
purulence, Anthonisen type, respiratory failure, non-invasive venti-
lation during hospitalization, respiratory intensive care unit admis-
sion, tracheal intubation, serum CRP values >40 mg/l,21 elevated
plasma ﬁbrinogen, positive bacterial culture of sputum or endotra-
cheal aspirate, and systemic corticosteroid treatment. The odds
ratio (OR) and 95% conﬁdence interval (CI) were calculated for
risk factors. All tests were two tailed; a p-value of <0.05 was
considered signiﬁcant.
A study found that the efﬁcacy of moxiﬂoxacin treatment for
patients with chronic bronchitis and AECOPD was 95%.22 A sub-
group analysis in another study showed that the clinical success
rate in the antibiotic group was 18% higher than that in the placebo
group for AECOPD with a PCT level <0.1 ng/ml,17 and another study
found that the success rate in the antibiotic group was 14% higher457 patie nts with AECOPD 
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Figure 1. Study ﬂow diagram (AECOPD, acute exacerbation of chronic obstthan that in the placebo group.21 Based on these studies, it was
estimated that the clinical success rate at 10 days after hospital
admission would be 95% in the antibiotic group and 80% in the
control group. With an a error of 0.05 and a power of 0.80, and
using MedCalc 15.0 statistical software to calculate the sample
size, it was determined that 88 cases would be needed in each arm.
Considering a 10% dropout rate, the ideal sample size was
calculated to be 194 patients in total. Thus, 194 patients with
AECOPD were assigned randomly to, and evenly split between, the
antibiotic and control groups according to the computer digital
table method.
3. Results
3.1. Subjects
A total 457 patients with AECOPD were screened at the time of
hospital admission. Of these, 97 had a PCT level 0.1 ng/ml: 42 had
a PCT level of 0.1–0.25 ng/ml and 55 had a PCT level >0.25 ng/ml.
These patients were excluded, along with a further 166 patients for
other reasons (Figure 1). scree ned for  eli gibilit y 
domize d 
Con trol group (n = 97)  
1 excluded for pn eumon ia 
according to chest CT  within 
48 hour s of admiss ion  
Con trol group 
ITT  populati on (n = 96)  
1 died during hospitalizati on 
30 da ys of fo llow-up (n = 95)  
1 die d dur ing 30-day  follo w-up  
ructive pulmonary disease; PCT, procalcitonin; ITT, intention-to-treat).
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and were assigned randomly, with even distribution, to the
antibiotic group and control group. Two patients in the antibiotic
group and one patient in the control group were conﬁrmed to have
pneumonia by chest CT within 48 h after hospital admission and
dropped out. The remaining 95 cases in the antibiotic group and
96 cases in the control group completed the study; no patient was
lost during the 30-day follow-up period.
3.2. Demographic characteristics
The baseline characteristics of randomized patients are shown
in Table 1. There was no signiﬁcant difference between the two
groups with regard to age, sex, smoking status, frequent
hospitalizations due to AECOPD in the previous year (2 times),
Anthonisen type, sputum purulence, antibiotic use within
3 months prior to admission, bronchiectasis, coronary heart
disease, hypertension, diabetes, history of cerebral infarction,Table 1
Baseline characteristics of 191 patients randomized to the antibiotic and control group
Characteristics Antibioti
(n = 95)
Age, years 73.4  1
Age 75 years 51 (53.7
Male 67 (70.5
Smoking
Former 79 (83.2
Current 18 (18.9
Frequent admissions in the previous year (2) 22 (23.2
Anthonisen typeb
Type I 25 (26.3
Type II 56 (58.9
Type III 14 (14.7
Type I and type II with sputum purulence 25 (26.3
Sputum purulence 25 (26.3
Domiciliary oxygen therapy 22 (23.2
Home mechanical ventilation 6 (6.3)
Antibiotic use prior to admission within 3 months 49 (51.6
Comorbidities
Bronchiectasis 22 (23.2
Coronary heart disease 31 (32.9
Hypertension 46 (43.8
Diabetes 15 (15.8
Chronic congestive heart failure 28 (29.5
History of cerebral infarction 6 (6.3)
Respiratory failure 37 (38.9
Mechanical ventilation 23 (24.2
Mechanical ventilation without purulent sputum 16 (16.8
Respiratory intensive care unit admission 21 (22.1
Systemic corticosteroid use 39 (45.9
Respiratory rate, beats/min 21.6  2
Heart rate, beats/min 89.7  1
Systolic blood pressure, mmHg 136.2  1
Diastolic blood pressure, mmHg 79.4  1
a Data are presented as the mean  standard deviation, or number (%).
b Type I: all of the Anthonisen criteria are present (increased dyspnea, increased sputum
criterion present.
Table 2
Comparison of lung function between the groups in the intention-to-treat populationa
Day of admission p-Va
Antibiotic
(n = 95)
Control
(n = 96)
FEV1 (% pre) 36.7  15.8 38.4  16.5 0.49
FVC (% pre) 48.7  19.5 45.5  17.5 0.28
FEV1/FVC 57.9  14.4 60.3  14.9 0.27
FEV1 (% pre), forced expiratory volume in one second (percentage of predicted); FVC 
expiratory volume in one second to forced vital capacity.
a Data are presented as the mean  standard deviation.chronic congestive heart failure, respiratory failure, respiratory
intensive care unit admission, or systemic corticosteroid use.
Lung function parameters of forced expiratory volume in one
second, forced vital capacity, and the ratio of forced expiratory
volume in one second to forced vital capacity, and arterial blood
gas analysis values of pH, PaO2, and PaCO2, were taken on hospital
admission and the day of hospital discharge. There was no
signiﬁcant difference in these values between the antibiotic group
and control group (Tables 2 and 3).
3.3. Clinical efﬁcacy analysis
In the antibiotic group, 76 cases received piperacillin–sulbac-
tam treatment, 18 cases received ceftazidime treatment, and one
patient received levoﬂoxacin treatment. Seventeen patients in
the control group were prescribed antibiotics after 3 days by the
attending physicians due to their clinical condition; piperacillin–
sulbactam was given to 13 patients and ceftazidime to four.sa
c group Control group
(n = 96)
p-Value
0.1 72.5  9.2 0.482
) 46 (47.9) 0.425
) 70 (72.9) 0.714
) 82 (85.4) 0.668
) 28 (29.2) 0.099
) 20 (20.8) 0.698
) 22 (22.9) 0.586
) 56 (58.3) 0.931
) 18 (18.8) 0.458
) 23 (24.0) 0.707
) 23 (24.0) 0.707
) 20 (20.8) 0.698
 8 (8.3) 0.593
) 42 (43.9) 0.279
) 20 (20.8) 0.698
) 33 (34.4) 0.799
) 46 (47.9) 0.559
) 13 (13.5) 0.661
) 22 (22.9) 0.303
 12 (12.5) 0.144
) 37 (38.5) 0.954
) 22 (22.9) 0.833
) 17 (17.7) 0.874
) 17 (17.7) 0.447
) 49 (51.0) 0.488
.7 21.2  3.0 0.322
8.5 88.7  18.0 0.730
8.2 135.7  15.7 0.827
2.1 79.5  10.4 0.943
 volume, and purulent sputum); type II: only two criteria present; type III: only one
lue Day of discharge p-Value
Antibiotic
(n = 59)
Control
(n = 69)
4 44.9  20.8 46.6  19.0 0.627
4 54.3  20.5 56.8  20.3 0.493
7 59.0  14.1 59.9  12.7 0.703
(% pre), forced vital capacity (percentage of predicted); FEV1/FVC, ratio of forced
Table 3
Comparison of arterial blood gas analysis values between the groups in the intention-to-treat populationa
Day of admission p-Value Day of discharge p-Value
Antibiotic
(n = 95)
Control
(n = 96)
Antibiotic
(n = 78)
Control
(n = 64)
pH value 7.43  0.06 7.42  0.07 0.187 7.45  0.05 7.45  0.05 0.940
PaCO2, mmHg 46.6  13.5 49.3  17.3 0.240 44.5  10.9 44.4  11.9 0.946
PaO2, mmHg 89.3  30.7 83.9  19.9 0.162 84.6  18.6 86.4  22.7 0.613
Oxygenation index 332  97 321  87 0.417 338  89 344  86 0.382
a Data are presented as the mean  standard deviation.
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rate in the control group (92/96, 95.8%) was similar to that in the
antibiotic group (89/95, 93.7%), with no signiﬁcant difference
between the two groups (Table 4) (p = 0.732). Six patients in the
antibiotic group were considered treatment failures on day 10 after
admission. Furthermore, ﬁve of them died either in hospital or
within 30 days of discharge. In the control group, four did not reach
treatment success on day 10 after admission and two died within
30 days of discharge.
According to the PP analysis, all 95 patients in the antibiotic
group completed at least 3 days of antibiotics and 79 patients in the
control group did not receive antibiotics within 10 days after
admission. The treatment success rate on day 10 after admission
was 98.7% (78/79) in the control group and 93.7% (89/95) in the
antibiotic group, with no signiﬁcant difference (p = 0.193).
The other 17 patients in the control group were given
antibiotics by the attending physicians (antibiotic use 17.7%) for
reasons including worsening of symptoms or signs (six cases) and
no improvement in symptoms or signs (11 cases). For these
17 patients, the average time from admission to receiving
antibiotics was 4.6  1.8 days. Three of these 17 cases did not reach
treatment success on day 10 after admission and one of them died.
Binary logistic regression analysis showed that age 75 years was a
risk factor associated with requiring antibiotic treatment in the
control group (OR 4.055, 95% CI 1.297–12.678; p = 0.012).
There was no signiﬁcant difference between the antibiotic
group and control group with regard to symptoms assessed by VAS,
the length of hospital stay, intubation rate, mortality during
hospitalization and during the 30 days of follow-up, re-hospitali-
zation due to AECOPD, and antibiotic use in the 30 days after
hospital discharge (ITT analysis, Table 4).
4. Discussion
Bacterial and viral infections are important factors in AECOPD.
Studies on the effect of antibiotics in patients with AECOPD have
been inconsistent. Patients admitted to intensive care units withTable 4
Clinical outcomes in the intention-to-treat populationa
Outcomes 
VAS
Day of hospital admission 
3 days after admission 
Day of hospital discharge 
Success rate at day 10 
Length of hospital stay, days 
Intubation 
AECOPD in the 30 days after hospital discharge 
Re-admission within 30 days of hospital discharge 
Antibiotic use within 30 days of hospital discharge 
Death during hospitalization or within 30 days of follow-up 
VAS, visual analog scale; AECOPD, acute exacerbation of chronic obstructive pulmonar
a Data are presented as the mean  standard deviation, or number (%).severe AECOPD are expected to beneﬁt from antibiotic treatment;
however, this remains to be determined for patients with less severe
AECOPD admitted to general wards.10 The GOLD guidelines suggest
that antibiotics should be given to patients with AECOPD who fall
into three categories: (1) those who have the three cardinal
symptoms of an increase in dyspnea, sputum volume, and sputum
purulence; (2) those who have two of the cardinal symptoms, if
increased purulence of sputum is one of the two symptoms; and (3)
those who require invasive or non-invasive mechanical ventilation.2
Currently, most patients admitted to a hospital with AECOPD
receive antibiotic therapy.5,6 In order to reduce the use of
antibiotics in this population, PCT has been employed as a speciﬁc
marker of bacterial infection to guide antibiotic treatment. There
have been only a few studies on PCT-guided antibiotic treatment
for patients with AECOPD. One study showed that PCT-guided
antibiotic treatment reduced antibiotic prescriptions from 72% to
40%.15 Moreover, lung function at 2 weeks and at 6 months, the
rate of re-hospitalization due to AECOPD, and the number of days
between AECOPD episodes were similar in the two groups.15 Two
other studies of PCT-guided antibiotic treatment for lower
respiratory tract infections also found that PCT-guided antibiotic
treatment decreased antibiotic exposure and that clinical out-
comes did not differ between the PCT-guided group and the
standard group.14,16 Previous studies on PCT-guided antibiotic
treatment for patients with AECOPD have used a PCT level of
>0.25 ng/ml to indicate the need for antibiotic therapy; in these
studies, the aim was to reduce antibiotic exposure.10,15 In reality,
PCT values are usually low in most patients with AECOPD; about
51–75% of patients have a PCT <0.1 ng/ml,15,17 and only 7–20% of
patients have a PCT level of >0.25 ng/ml.15,17,23 So far, there have
been no reports on whether antibiotic treatment is of beneﬁt to
AECOPD patients with low PCT levels.
In this study, the percentage of patients with a PCT of <0.1 ng/
ml was 78.8% (360/457). It was hypothesized that patients with
AECOPD and a PCT of <0.1 ng/ml may beneﬁt from antibiotic
therapy. Moreover, in order to guarantee the authenticity of this
study, broad-spectrum antibiotics that cover common pathogensAntibiotic
(n = 95)
Control
(n = 96)
p-Value
19.5  8.3 18.8  7.7 0.562
13.4  7.2 12.6  4.9 0.415
6.1  4.9 5.5  3.8 0.405
89 (93.7) 92 (95.8) 0.732
10.9  8.1 9.9  5.1 0.310
1 (1.1) 2 (2.1) 1.000
17 (17.9) 11 (11.5) 0.209
13 (13.7) 8 (8.3) 0.237
17 (17.9) 12 (12.5) 0.299
5 (5.63) 2 (2.1) 0.242
y disease.
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selected for treatment. To determine if antibiotic treatment is
beneﬁcial in terms of a more rapid improvement in symptoms,
patients were taught to conduct a self-rating VAS for four main
symptoms: dyspnea, fatigue, cough, and sputum purulence.
However, it was found that patients in the control group
achieved a similar treatment success rate with less antibiotic use
compared with the patients in the antibiotic group. What is more,
ﬁve patients in the antibiotic group died as compared to two
patients in the control group, although the difference was not
signiﬁcant. Based on these results, it is suggested that antibiotics
be withheld initially from patients with AECOPD and a PCT level of
<0.1ng/ml; whether and when antibiotics should be added to the
patient’s treatment protocol should be guided by the patient’s
clinical condition and determined by the attending physician. This
strategy will provide an ideal treatment success rate without any
short-term adverse clinical outcomes.
Studies have shown that sputum purulence and CRP 40 mg/dl
are predictive risk factors for treatment failure in patients with
AECOPD,23 and sputum purulence-guided antibiotic therapy can be
used in patients with AECOPD.11,12 In the present study, using binary
logistic regression analysis, it was found that only age 75 years was
a predictive risk factor for requiring antibiotic treatment in the
control group (OR 4.055, 95% CI 1.297–12.678; p = 0.012); sputum
purulence and CRP 40 mg/dl may not be the indications for
antibiotic use in patients with AECOPD and PCT values <0.1 ng/ml.
This study had several limitations. First, antibiotic use 3 months
prior to admission in patients was high. The reason for this is that
many patients with AECOPD in China often choose to take antibiotics
at home. Second, the follow-up assessment was only conducted over
30 days. Long-term outcome evaluations are needed. Third, although
piperacillin–sulbactam, ceftazidime, and levoﬂoxacin are broad-
spectrum antibiotics, none of them covers all pathogens. For
instance, they do not cover methicillin-resistant Staphylococcus
aureus or multidrug-resistant Acinetobacter baumannii. Piperacillin–
sulbactam and ceftazidime are ineffective against atypical patho-
gens such as Mycoplasma pneumoniae, and ceftazidime and
levoﬂoxacin are ineffective against multidrug-resistant P.
aeruginosa. Finally, this study did not involve patients with PCT in
the range of 0.1–0.25 ng/ml; whether these patients could beneﬁt
from antibiotic treatment also needs to be studied further.
In conclusion, in this randomized clinical trial it was found that
antibiotic treatment was no better than placebo in AECOPD
patients with a PCT level <0.1 ng/ml.
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